Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium
| Journal | Volume 79 - 2016 |
| Issue | Fasc.2 - Original articles |
| Author(s) | Catharina Matheï, Stefan Bourgeois, Sarah Blach, Christian Brixko, Jean-Pierre Mulkay, Homie Razavi, Geert Robaeys |
| Full article |
 VIEW FREE PDF |
| (1) Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium ; (2) ZNA Campus Stuivenberg, Antwerp, Belgium ; (3) Center for Disease Analysis, Louisville, CO. USA ; (4) Department of Gastroenterology and Digestive Oncology, CHR Citadelle, Liege, Belgium ; (5) Hepato-gastroenterology, CHU Saint-Pierre, Brussels, Belgium ; (6) Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, Genk, Belgium ; (7) Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium ; (8) Department of Hepatology, UZ Leuven, Leuven, Belgium. |
|
Background and Aims : In 2010, there were an estimated 10 100 PWID in Belgium and 43% (34%-57%) were HCV infected. Un- derstanding HCV transmission dynamics in high-risk populations and assessing the potential impact of improved HCV treatment strategies requires robust epidemiological data and mathematical modeling. Methods : HCV transmission was modeled using cohorts to track HCV incidence and prevalence among active PWID in the general PWID population, OST and NSP. Model assumptions were derived from published literature and expert consensus. The relative im- pact of increasing the number of PWID treated with new oral DAAs was considered. Results : If the current transmission paradigm continues, there will be 2645 HCV-infected PWID in 203O.Annually treating 30 (1% of 2015 population) or 120 (4% of 2015 population) HCV-in- fected PWID with oral DAAs will result in 5% and 25% reductions, respectively, in HCV-infected PWID by 203O.Treating 370 PWID annually (12.5% of 2015 population) will result in a > 90% reduc- tion by 2030. |
|
© Acta Gastro-Enterologica Belgica. PMID 27382943 |
